|
| 36370742 | Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. | Lancet Haematol | 2023 |
| 38066868 | The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy. | Hematology Am Soc Hematol Educ Program | 2023 |
| 37814121 | E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. | Leukemia | 2023 |
| 37086447 | A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. | Hematol Oncol | 2023 |
| 37196640 | Olutasidenib: from bench to bedside. | Blood Adv | 2023 |
| 36724515 | Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. | Blood Adv | 2023 |
| 36626250 | Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. | Blood | 2023 |
| 36741714 | The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. | Front Oncol | 2023 |
| 35096610 | <i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. | Front Oncol | 2022 |
| 36467830 | Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia. | EJHaem | 2022 |
| 36338830 | The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. | Leuk Res Rep | 2022 |
| 36107670 | Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. | Cancer | 2022 |
| 35937938 | Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. | Cancer Manag Res | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 36077629 | Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients. | Cancers (Basel) | 2022 |
| 34031004 | Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone. | Clin Lymphoma Myeloma Leuk | 2021 |
| 35822053 | CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients. | Front Aging | 2021 |
| 33495312 | Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. | Clin Cancer Res | 2021 |
| 33483617 | Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. | Leukemia | 2021 |
| 33772143 | Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. | Leukemia | 2021 |
| 34439266 | A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. | Cancers (Basel) | 2021 |
| 34789825 | Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. | Leukemia | 2021 |
| 34771451 | Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. | Cancers (Basel) | 2021 |
| 34178531 | Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy. | Cureus | 2021 |
| 34172893 | Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. | Leukemia | 2021 |
| 31527168 | Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. | Clin Cancer Res | 2020 |
| 31841594 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. | Blood | 2020 |
| 33139625 | Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. | Cancers (Basel) | 2020 |
| 32995351 | Discordance Between Radiologic Findings and Molecular Testing in Patients With Underlying Hematologic Malignancy and Coronavirus Disease 2019. | Open Forum Infect Dis | 2020 |
| 32284317 | The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia. | Clin Cancer Res | 2020 |
| 32477862 | Spontaneous remission of acute myeloid leukemia with NF1 alteration. | Leuk Res Rep | 2020 |
| 32380538 | Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. | Blood Adv | 2020 |
| 30645972 | CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. | Cancer Cell | 2019 |
| 31888052 | A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. | Cancers (Basel) | 2019 |
| 31484534 | Correction to: Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia. | J Transl Med | 2019 |
| 31061068 | Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. | Clin Cancer Res | 2019 |
| 31109340 | Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia. | J Transl Med | 2019 |
| 29192651 | Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. | Mod Pathol | 2018 |
| 30135719 | Recent advances in the understanding and treatment of acute myeloid leukemia. | F1000Res | 2018 |
| 29920189 | Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. | J Clin Invest | 2018 |
| 29894694 | CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. | Cancer Cell | 2018 |
| 30423301 | CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. | Cancer Cell | 2018 |
| 30267380 | Leveraging Hypomethylating Agents for Better MDS Therapy. | Curr Hematol Malig Rep | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 29175379 | Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. | Leuk Res | 2018 |
| 28575698 | Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. | Leuk Res | 2017 |
| 28157218 | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. | Blood Cancer J | 2017 |
| 29093807 | Biological and clinical implications of telomere dysfunction in myeloid malignancies. | Ther Adv Hematol | 2017 |
| 28784769 | Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. | Proc Natl Acad Sci U S A | 2017 |
| 28696354 | A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. | Int J Mol Sci | 2017 |